RecruitingNot Applicable

Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation Study

Germany380 participantsStarted 2023-01-31

Plain-language summary

The purpose of the study is to validate recently identified biomarkers for the identification of PCOS in adolecent and young adult women.

Who can participate

Age range15 Years – 25 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female subjects age 15-25 years * Signed written informed consent Exclusion Criteria: * Less than 1 years from onset of menarche * Use of hormonal contraceptives * Documented ongoing pregnancy * Major ovarian abnormalities, including subject with only one ovary, cysts and solid masses \> 2 cm as detected by transvaginal ultrasound * Malignancy ( documented malignancy, documentation of current radiation therapy or chemotherapy in medical record)

What they're measuring

The validation of new potential biomarkers for aid in the diagnoisis of PCOS in adolescent and young adult women

Timeframe: Baseline

Trial details

NCT IDNCT06642831

SponsorUniversity Hospital Erlangen

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12

Contact for this trial

Laura Lotz, Dr. med.

+49 9131 85 44023 laura.lotz@uk-erlangen.de

View on ClinicalTrials.gov More Polycystic Ovarian Syndrome (PCOS) trials